Jump to content

Another new PMSA-linked radioisotope enters clinical trials in prostate cancer

Paul Edwards

Recommended Posts

"Another new form of radioisotope, copper-64 (64Cu), has recently undergone Phase I clinical testing for similar uses when linked to the PSMA-617 ligand.  One of the potential benefits of a 64Cu-PSMA imaging agent is that it is more stable and has a longer half-life than 68Ga.  This means that this imaging agent could be made at a central facility and distributed from there to clinical PET scan centers that don’t have the radiochemistry capabilities necessary for the preparation of 68Ga-PSMA imaging agents."


The New Prostate Cancer Infolink has a report on the trial carried out at two nuclear medicine centers (in Vienna, Austria, and Bad Berka, Germany).



Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...